comparemela.com

Page 6 - Zacks Medical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cresco Labs Inc (CRLBF) Reports Q2 Loss, Tops Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -66.67% and 1.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cresco labs incZacks investment researchWhile cresco labs incHigh tide incCresco labsZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankHigh tideZacks investmentZacks rankStimate revisionsQuarterly loss

Inotiv, Inc (NOTV) Q3 Earnings Miss Estimates

Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -73.08% and 6.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks investment researchInotiv incWhile inotiv incHoldings corpZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankZacks investmentZacks rankQuarterly earningsStimate revisionsPs estimatesOnsensus estimateConsensus eps estimate

Apyx Medical (APYX) Reports Q2 Loss, Misses Revenue Estimates

Apyx (APYX) delivered earnings and revenue surprises of 8.33% and 4.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Phibro animal healthZacks investment researchApyx medicalZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankAnimal healthZacks investmentStimate revisionsOnsensus estimatePs estimatesConsensus eps estimateArnings surprise

Aurora Cannabis Inc (ACB) Reports Q4 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50% and 19.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cooper companiesZacks investment researchWhile aurora cannabis incAurora cannabis incAurora cannabisZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankCooper companieZacks investment

Bionano Genomics, Inc (BNGO) Reports Q2 Loss, Tops Revenue Estimates

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.78% and 6.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Senti biosciences incZacks investment researchWhile bionano genomics incBionano genomics incBionano genomicsZacks consensus estimateZacks medicalZacks rankStrong buyZacks industry rankZacks investmentZacks rankStimate revisionsQuarterly lossPs estimatesConsensus eps estimate

vimarsana © 2020. All Rights Reserved.